Scalp, palmoplantar and nail psoriasis

Scalp, palmoplantar and nail (hard-to-treat) psoriasis efficacy vs. placebo in an exploratory pooled analysis^1,2

This is an exploratory pooled analysis and results should be interpreted with caution. P-values are nominal

Week 16 (pooled analysis), SOTYKTU outcomes vs. placebo in tough-to-treat areas:^1,2

A chart showing week 16 (pooled analysis), SOTYKTU outcomes vs. placebo in tough-to-treat areas:

Adapted from SOTYKTU EPAR.
Pooled PSO-1/PSO-2: SOTKYTU (n=843), placebo (n=421).¹

An icon representing pinch to zoom Pinch & zoom to explore

*ss-PGA 0/1 score or 0 or 1 includes patients with baseline Scalp Psoriasis PGA score 0/1 of ≥3.
**pp-PGA 0/1 score of 0 or 1 includes patients with a baseline pp-PGA score ≥3.
^†PGA-F 0/1 includes patients with a baseline PGA-F score ≥3.
Missing data were imputed using NRI method.
NRI, non-responder imputation; pp-PGA, palmoplantar Physician’s Global Assessment; ss-PGA, scalp-specific Physician’s Global Assessment; PGA-F, Physician’s Global Assessment-Fingernails.

References

SOTYKTU. European Product Assessment Report (EPAR). 26 January 2023. Available at https://www.ema.europa.eu/en/documents/assessment-report/sotyktu-epar-public-assessment-report_en.pdf (Accessed August 2023).
Crowley JJ. Challenges in Psoriasis Treatment: Nail, Scalp, and Palmoplantar Involvement. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham.